Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Late-stage labeling of diverse peptides and proteins with iodine-125

A. Marek, B. Brož, M. Kriegelstein, G. Nováková, J. Hojcsková, M. Blechová, L. Žáková, J. Jiráček, L. Maletínská

. 2025 ; 15 (7) : 101198. [pub] 20250117

Status neindexováno Jazyk angličtina Země Čína

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25020886

The preparation of specifically iodine-125 (125I)-labeled peptides of high purity and specific activity represents a key tool for the detailed characterization of their binding properties in interaction with their binding partners. Early synthetic methods for the incorporation of iodine faced challenges such as harsh reaction conditions, the use of strong oxidants and low reproducibility. Herein, we review well-established radiolabeling strategies available to incorporate radionuclide into a protein of interest, and our long-term experience with a mild, simple and generally applicable technique of 125I late-stage-labeling of biomolecules using the Pierce iodination reagent for the direct solid-phase oxidation of radioactive iodide. General recommendations, tips, and details of optimized chromatographic conditions to isolate pure, specifically 125I-mono-labeled biomolecules are illustrated on a diverse series of (poly)peptides, ranging up to 7.6 kDa and 67 amino acids (aa). These series include peptides that contain at least one tyrosine or histidine residue, along with those featuring disulfide crosslinking or lipophilic derivatization. This mild and straightforward late-stage-labeling technique is easily applicable to longer and more sensitive proteins, as demonstrated in the cases of the insulin-like growth factor binding protein-3 (IGF-BP-3) (29 kDa and 264 aa) and the acid-labile subunit (ALS) (93 kDa and 578 aa).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25020886
003      
CZ-PrNML
005      
20251014150437.0
007      
ta
008      
251007s2025 cc f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jpha.2025.101198 $2 doi
035    __
$a (PubMed)40741338
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a cc
100    1_
$a Marek, Aleš $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
245    10
$a Late-stage labeling of diverse peptides and proteins with iodine-125 / $c A. Marek, B. Brož, M. Kriegelstein, G. Nováková, J. Hojcsková, M. Blechová, L. Žáková, J. Jiráček, L. Maletínská
520    9_
$a The preparation of specifically iodine-125 (125I)-labeled peptides of high purity and specific activity represents a key tool for the detailed characterization of their binding properties in interaction with their binding partners. Early synthetic methods for the incorporation of iodine faced challenges such as harsh reaction conditions, the use of strong oxidants and low reproducibility. Herein, we review well-established radiolabeling strategies available to incorporate radionuclide into a protein of interest, and our long-term experience with a mild, simple and generally applicable technique of 125I late-stage-labeling of biomolecules using the Pierce iodination reagent for the direct solid-phase oxidation of radioactive iodide. General recommendations, tips, and details of optimized chromatographic conditions to isolate pure, specifically 125I-mono-labeled biomolecules are illustrated on a diverse series of (poly)peptides, ranging up to 7.6 kDa and 67 amino acids (aa). These series include peptides that contain at least one tyrosine or histidine residue, along with those featuring disulfide crosslinking or lipophilic derivatization. This mild and straightforward late-stage-labeling technique is easily applicable to longer and more sensitive proteins, as demonstrated in the cases of the insulin-like growth factor binding protein-3 (IGF-BP-3) (29 kDa and 264 aa) and the acid-labile subunit (ALS) (93 kDa and 578 aa).
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Brož, Břetislav $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
700    1_
$a Kriegelstein, Michal $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
700    1_
$a Nováková, Gabriela $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
700    1_
$a Hojcsková, Jana $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
700    1_
$a Blechová, Miroslava $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
700    1_
$a Žáková, Lenka $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
700    1_
$a Jiráček, Jiří $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
700    1_
$a Maletínská, Lenka $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
773    0_
$w MED00205566 $t Journal of pharmaceutical analysis $x 2214-0883 $g Roč. 15, č. 7 (2025), s. 101198
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40741338 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20251007 $b ABA008
991    __
$a 20251014150443 $b ABA008
999    __
$a ok $b bmc $g 2410956 $s 1259042
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 15 $c 7 $d 101198 $e 20250117 $i 2214-0883 $m Journal of pharmaceutical analysis $n J Pharm Anal $x MED00205566
LZP    __
$a Pubmed-20251007

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...